Neurocentrx

Neurocentrx Pharma Limited is a private Scottish clinical-stage company developing NRCx-201 (Keticap) — an immediate-release, abuse-deterrent oral ketamine capsule paired with proprietary digital prescription safety software for regulated clinic-to-home care. Founded in 2013 by CEO Carmel Reilly at the University of Edinburgh, the company raised ~$6.15M total including a September 2025 seed extension (~$5M) led by the Wellcome Trust to fund a Phase 2 proof-of-concept trial in treatment-resistant bipolar depression (planned Q1 2026). Phase 1 (King's College London, EudraCT 2019-001019-22, n=18, 40–240mg) completed early 2023 with positive results: well-tolerated at all doses, no SAEs, PK comparable to IV/intranasal esketamine, no cognitive impairment. MHRA has indicated NRCx-201 is suitable for direct Phase 3 submission for TRD (company plans Phase 2 first). Key investors: Wellcome Trust, Neo Kuma Ventures, O2h Ventures, Equity Gap.